Abstract
The clinical indications of CEBs have grown steadily over the last 25 years since the first CEB, prenylamine was introduced in 1960. Since that time more than 10 compounds that can be called CEBs have been marketed internationally (Table 7). The much larger number of compounds invarious stages of development (see Sect. 2) suggests that many more will soon be available. The clinical experience and therapeutic potential of CEBs has been the subject of a number of recent reviews 114,127, 149, 188, 194, 201, 210, 270, 273, 275).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Smith, R.D., Wolf, P.S., Regan, J.R., Jolly, S.R. (1988). Therapeutic Indications. In: The Emergence of Drugs which Block Calcium Entry. Progress in Clinical Biochemistry and Medicine, vol 6. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73228-7_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-73228-7_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73230-0
Online ISBN: 978-3-642-73228-7
eBook Packages: Springer Book Archive